Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis

To the Editor On behalf of my coauthors, I write to report corrections needed in the Original Investigation, “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial,” that was published online first on August 4, 2021, and in the September 2021 issue of JAMA Dermatology.
Source: JAMA Dermatology - Category: Dermatology Source Type: research